Analyst firm Mizuho maintained its Outperform rating on HCA Healthcare with a steady price target of $425.00, following HCA's third-quarter results. Similarly, Cantor Fitzgerald maintained a positive stance, raising the price target to $405 from the previous target of $392. Both firms expressed confidence in HCA Healthcare's ongoing business strength and future prospects.